Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpt.803PMID 28758192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.

  2017cited by this paper
• Development of a new ARCHITECT automated periostin immunoassay.

  2017cited by this paper
• A model‐based longitudinal meta‐analysis of FEV1 in randomized COPD trials

  2016cited by this paper
• Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

  2016cited by this paper
• Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

  2015cited by this paper
• STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma

  2015cited by this paper
• Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

  2015cited by this paper
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

  2015cited by this paper
• Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline.

  2014cited by this paper
• Genome-wide interrogation of longitudinal FEV1 in children with asthma.

  2014cited by this paper
• Asthma phenotypes and endotypes: an evolving paradigm for classification.

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels.

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels

  2013cited by this paper
• Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

  2013influential reference
• Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

  2012influential reference
• A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

  2012cited by this paper
• Lebrikizumab treatment in adults with asthma.

  2011cited by this paper
• Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

  2011cited by this paper
• Airway fibroblasts in asthma manifest an invasive phenotype.

  2011cited by this paper
• An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

  2010cited by this paper
• A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

  2010cited by this paper
• Semiparametric Distributions With Estimated Shape Parameters

  2009cited by this paper
• Increased sputum and bronchial biopsy IL-13 expression in severe asthma.

  2008cited by this paper
• Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

  2007cited by this paper
• Effect of aging on respiratory system physiology and immunology

  2006cited by this paper
• Minimal Clinically Important Differences in COPD Lung Function

  2005cited by this paper
• This information is current as Production That Are Sufficient for Rapid Cytokine Transcripts during Lineage Differentiation Acquire Constitutive IL-4 and IL-13 Mast Cells , Basophils , and Eosinophils

  2004influential reference
• Effects of cytokines on contractile and dilator responses of airway smooth muscle

  2002cited by this paper
• Variability and lack of predictive ability of asthma end-points in clinical trials

  2002cited by this paper
• Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts.

  1996cited by this paper
• Interleukin-13 and interleukin-4 are coexpressed in atopic asthma.

  1996cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper

• Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications

  2025cites this paper
• Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1 ) in Uncontrolled Moderate‐To‐Severe Asthma

  2025cites this paper
• Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

  2022cites this paper
• Anti-Interleukin Biologics for the treatment of the Atopic March Diseases

  2021cites this paper
• IL-13 Impairs Tight Junctions in Airway Epithelia

  2019cites this paper
• The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-analysis.

  2019cites this paper
• Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.

  2018cites this paper
• Tralokinumab for severe , uncontrolled asthma : the STRATOS 1 and 2 randomised , placebo-controlled , phase 3 clinical trials

  2018cites this paper
• Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.

  2018cites this paper
• A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

  2017cites this paper